Eli Lilly and Company Limited is a global pharmaceutical company headquartered in Basingstoke, England. Established in 1934, Eli Lilly has a long history of developing and manufacturing pharmaceutical products across a diverse range of therapeutic areas. The company operates as a limited company, registered under SIC code - 21100, focusing on the manufacture of basic pharmaceutical products. Currently, Eli Lilly is actively adjusting the pricing strategy for its weight-loss drug, Mounjaro, within the United Kingdom. This strategic decision follows significant pressure from the Trump administration, resulting in a proactive effort to mitigate cost pressures in the U.S. market. The company’s core business encompasses research, development, and commercialization of pharmaceutical products, targeting a broad spectrum of health conditions. Eli Lilly maintains a significant international presence, with operations spanning numerous countries. The company’s size is estimated to be substantial, reflecting its investment in research and development, manufacturing, and global distribution networks. It prioritizes innovation and strategic partnerships to expand its product portfolio and market reach. The company is actively seeking to expand its workforce through Visa programs, indicating a commitment to growth and operational efficiency.

Eli Lilly and Company Limited is a global pharmaceutical company headquartered in Basingstoke, England. Established in 1934, Eli Lilly has a long history of developing and manufacturing pharmaceutical products across a diverse range of therapeutic areas. The company operates as a limited company, registered under SIC code - 21100, focusing on the manufacture of basic pharmaceutical products. Currently, Eli Lilly is actively adjusting the pricing strategy for its weight-loss drug, Mounjaro, within the United Kingdom. This strategic decision follows significant pressure from the Trump administration, resulting in a proactive effort to mitigate cost pressures in the U.S. market. The company’s core business encompasses research, development, and commercialization of pharmaceutical products, targeting a broad spectrum of health conditions. Eli Lilly maintains a significant international presence, with operations spanning numerous countries. The company’s size is estimated to be substantial, reflecting its investment in research and development, manufacturing, and global distribution networks. It prioritizes innovation and strategic partnerships to expand its product portfolio and market reach. The company is actively seeking to expand its workforce through Visa programs, indicating a commitment to growth and operational efficiency.